Valuation: Protalix BioTherapeutics, Inc.

Market Cap 189M 162M 152M 139M 262M 18.1B 266M 1.79B 701M 9.08B 711M 695M 30.01B P/E 2026 *
12.4x
P/E 2027 * 42.7x
Enterprise Value 189M 162M 152M 139M 262M 18.1B 266M 1.79B 701M 9.08B 711M 695M 30.01B EV / Sales 2026 *
2.37x
EV / Sales 2027 * 2.78x
Free-Float
96.12%
Yield 2026 *
-
Yield 2027 * -
1 day-0.64%
1 week-1.48%
Current month-1.90%
1 month-3.53%
3 months+15.67%
6 months-24.02%
Current year+29.17%
1 week 2.17
Extreme 2.17
2.38
1 month 2.17
Extreme 2.17
2.7
Current year 1.72
Extreme 1.72
3.19
1 year 1.52
Extreme 1.5201
3.19
3 years 0.82
Extreme 0.8214
3.19
5 years 0.7
Extreme 0.7
3.55
10 years 0.7
Extreme 0.7
15.15
Manager TitleAgeSince
Chief Executive Officer 59 29/06/2019
Director of Finance/CFO 57 23/08/2025
Chief Tech/Sci/R&D Officer - 31/05/2024
Director TitleAgeSince
Director/Board Member 73 30/06/2008
Director/Board Member 83 31/10/2014
Director/Board Member 59 29/06/2019
Date Insider Type Main position Quantity % Market Cap.
19/12/25 Buy

Chief Executive Officer

56,000 0.0696%
18/11/25 Sell

Director

168 0.0002%
03/09/25 Free

Chief Operating Officer

75,000 0.0941%
Change 5-day change 1-year change 3-year change Capi.($)
-0.64%-1.48%+48.09%+21.09% 189M
-1.43%+4.38%+78.89%+129.42% 1,141B
-1.26%+3.56%+51.76%+62.18% 659B
-0.99%+5.78%+26.86%+76.69% 470B
+0.15%+2.01%+40.85%+45.34% 366B
-1.37%+2.10%+23.43%+40.38% 302B
-1.19%+2.17%-0.12%+12.07% 254B
-2.09%+4.16%+46.81%+66.94% 239B
-1.04%-0.39%-14.03%-52.89% 207B
-2.54%+4.66%+21.77%+90.39% 183B
Average -1.20%+2.66%+32.43%+49.16% 382.12B
Weighted average by Cap. -1.23%+4.31%+44.76%+72.80%

Financials

2026 *2027 *
Net sales 79.8M 68.45M 63.92M 58.64M 110M 7.63B 112M 754M 295M 3.83B 300M 293M 12.65B 68.19M 58.5M 54.62M 50.12M 94.24M 6.52B 95.79M 645M 252M 3.27B 256M 250M 10.81B
Net income 15.38M 13.19M 12.32M 11.3M 21.25M 1.47B 21.6M 145M 56.9M 737M 57.73M 56.47M 2.44B 4.46M 3.83M 3.57M 3.28M 6.17M 427M 6.27M 42.18M 16.52M 214M 16.76M 16.39M 707M
Net Debt - -
Logo Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of uncontrolled gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase) - a chemically modified enzyme to treat uncontrolled gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate. Its product includes Elelyso and Elfabrio. Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease.
Employees
226
Date Price Change Volume
20/08/26 US$2.325 -1.06% 108,209
19/08/26 US$2.350 +0.43% 477,242
18/08/26 US$2.340 +2.18% 280,506
17/08/26 US$2.290 +3.15% 1,075,616
14/08/26 US$2.220 -5.93% 995,919
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
2.350USD
Average target price
11.00USD
Spread / Average Target
+368.09%

Quarterly revenue - Rate of surprise